Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation

Transplantation Proceedings

Volumn 42, Issue 9, 2010, Pages 3503-3506

  Ciancio, G ^a   Gaynor, J J ^a   Roth, D ^b   Kupin, W ^b   Hanson, L ^a   Tueros, L ^a   Zarak, A ^a   Ruiz, P ^b   Burke III, G W ^a  

^a Florida   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CREATININE; DACLIZUMAB; HLA ANTIGEN; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE KIDNEY TUBULE NECROSIS; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; NEW ONSET DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BIOLOGICAL MARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; FLORIDA; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STEROIDS; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 78649469354     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.08.045     Document Type: Article

References (15)

1. F. Vincenti, R. Kirkman, and S. Light Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation Daclizumab Triple Therapy Study Group N Engl J Med 338 1998 161
2. B.D. Kahan, P.R. Rajagopalan, M. Hall United States Simulet Renal Study Group Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2- receptor monoclonal antibody Transplantation 67 1999 276
3. G. Ciancio, G.W. Burke, and K. Suzart Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients Transplantation 73 2002 1100
4. A.O. Gaber, M.R. First, and R.J. Tesi Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplant Transplantation 66 1998 29
5. W.C. Goggins, M.A. Pascual, and J.A. Powelson A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients Transplantation 76 2003 798
6. A.J. Matas, R. Kandaswamy, and A. Humar Long-term immunosuppression, without maintenance prednisone, after kidney transplantation Ann Surg 240 2004 510
7. S.J. Knechtle, J.D. Pirsch, and H.J. Fechner Jr Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study Am J Transplant 3 2003 722
8. G. Ciancio, G.W. Burke, and J.J. Gaynor The use of Campath-1H as induction therapy in renal transplantation: preliminary results Transplantation 78 2004 426
9. C.J. Watson, J.A. Bradley, and P.J. Friend Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years Am J Transplant 5 2005 1347
10. H.P. Tan, J. Donaldson, and A. Basu Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up Am J Transplant 9 2009 355
11. G. Ciancio, G.W. Burke, and J.J. Gaynor A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation I. Drug interactions and rejection at one year Transplantation 77 2004 244
12. G. Ciancio, G.W. Burke, and J.J. Gaynor A randomized trial of three transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring Transplantation 80 2005 457
13. G. Ciancio, G.W. Burke, and J.J. Gaynor A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow up Clin Transplant 22 2008 200
14. A.B. Chkhotua, T. Klein, and E. Shabtai Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplant under current immunosuppressive protocols Urology 62 2003 1002
15. K.L. Hardinger, M.A. Schnitzler, and M.J. Koch Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience Transplantation 81 2006 1285